Comparative Pharmacology
Head-to-head clinical analysis: LANOXICAPS versus LANOXIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LANOXICAPS versus LANOXIN.
LANOXICAPS vs LANOXIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibition of Na+/K+-ATPase pump, leading to increased intracellular sodium and calcium, positive inotropy, and increased vagal tone.
Inhibits Na+/K+ ATPase, increasing intracellular Ca2+ via Na+/Ca2+ exchange, enhancing cardiac contractility and reducing conduction through AV node.
0.125-0.25 mg orally daily, initially 0.25 mg daily in divided doses 3-4 times daily, maintenance 0.125-0.25 mg daily.
0.125-0.25 mg orally once daily; loading dose 0.5-0.75 mg orally divided over 24-48 hours if rapid digitalization required.
None Documented
None Documented
Terminal elimination half-life is approximately 5-7 days (120-168 hours) in patients with normal renal function; prolonged in renal impairment, necessitating dose adjustment.
Terminal elimination half-life is approximately 36-48 hours in patients with normal renal function; prolonged to 3.5-5 days in anuria.
Digitoxin is primarily excreted via the kidneys (approx. 70-80%) as unchanged drug and metabolites; the remainder undergoes biliary/fecal elimination (approx. 20-30%).
Renal excretion of unchanged drug (60-80%) and biliary/fecal elimination (20-40%).
Category C
Category C
Cardiac Glycoside
Cardiac Glycoside